Abstract
Penile erection is a complex physiologic event resulting from the interactions of the nervous system on a highly specialized vascular organ. Activation of central nervous system melanocortinergic (MC) receptors with either endogenous or synthetic melanotropic ligands may initiate and/or facilitate spontaneous penile erection. While the CNS contains principally the MC3 and MC4 receptor subtypes, there is conflicting data as to which receptor mediates erection. Although the MC4R is emerging as the principle effector of MC induced erection, the role of the MC3R is poorly understood. Manipulation of each receptor subtype with newly synthesized receptor specific agonists and antagonists, as well as knockout mice, has elucidated their individual contributions. Novel data from our laboratories suggests that antagonism of forebrain MC3R may enhance melanocortin-induced erections. Furthermore, melanocortin agents may interact with better-studied systems such as oxytocinergic pathways at the hypothalamic, brainstem or spinal level. Current therapies for erectile dysfunction target end organ vascular tissue. Manipulation of MC receptors may provide an alternative, centrally mediated therapeutic approach for erectile and other sexual dysfunctions. The non-specific “ superpotent ” MC agonist, PT-141, which is the carboxylate derivative of MT-II, has reached phase II human trials. Through their centrally mediated activity, melanocortin agonists have potential to treat erectile dysfunction as well as possible applications to the unmet medical needs of decreased sexual motivation and loss of libido.
Keywords: hindbrain melanocortin signaling, npgi neurons, thiq, pt-141, erectogenic, melanotan-II
Current Topics in Medicinal Chemistry
Title: Melanocortin Receptors, Melanotropic Peptides and Penile Erection
Volume: 7 Issue: 11
Author(s): Hunter Wessells, Todd W. Vanderah, Victor J. Hruby, Preeti Balse-Srinivasan, Stephen H. King and Alexander V. Mayorov
Affiliation:
Keywords: hindbrain melanocortin signaling, npgi neurons, thiq, pt-141, erectogenic, melanotan-II
Abstract: Penile erection is a complex physiologic event resulting from the interactions of the nervous system on a highly specialized vascular organ. Activation of central nervous system melanocortinergic (MC) receptors with either endogenous or synthetic melanotropic ligands may initiate and/or facilitate spontaneous penile erection. While the CNS contains principally the MC3 and MC4 receptor subtypes, there is conflicting data as to which receptor mediates erection. Although the MC4R is emerging as the principle effector of MC induced erection, the role of the MC3R is poorly understood. Manipulation of each receptor subtype with newly synthesized receptor specific agonists and antagonists, as well as knockout mice, has elucidated their individual contributions. Novel data from our laboratories suggests that antagonism of forebrain MC3R may enhance melanocortin-induced erections. Furthermore, melanocortin agents may interact with better-studied systems such as oxytocinergic pathways at the hypothalamic, brainstem or spinal level. Current therapies for erectile dysfunction target end organ vascular tissue. Manipulation of MC receptors may provide an alternative, centrally mediated therapeutic approach for erectile and other sexual dysfunctions. The non-specific “ superpotent ” MC agonist, PT-141, which is the carboxylate derivative of MT-II, has reached phase II human trials. Through their centrally mediated activity, melanocortin agonists have potential to treat erectile dysfunction as well as possible applications to the unmet medical needs of decreased sexual motivation and loss of libido.
Export Options
About this article
Cite this article as:
Hunter Wessells , Todd W. Vanderah , Victor J. Hruby , Preeti Balse-Srinivasan , Stephen H. King and Alexander V. Mayorov , Melanocortin Receptors, Melanotropic Peptides and Penile Erection, Current Topics in Medicinal Chemistry 2007; 7 (11) . https://dx.doi.org/10.2174/1568026610707011111
DOI https://dx.doi.org/10.2174/1568026610707011111 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis, Characterization and Physico-chemical Properties of New 2-(4- Arylpiperazine-1-yl)-1-(3-methylbenzofuran-2-yl)ethanoles as Potential Antihypertensive Agents
Current Organic Chemistry Dopamine Administration in Very Low Birth Weight Preterm Infants:Emerging Issues on Endocrine Effects
Current Pediatric Reviews Is the Therapeutic Potential of Stem Cells for Myocardial Regeneration Limited by Proarrhythmic Effects?
Current Cardiology Reviews Exploitation of Some Natural Products for the Prevention and/or Nutritional Treatment of SARS-CoV2 Infection
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacogenetically Tailored Treatments for Heart Disease
Current Pharmaceutical Design Members of CRF Family and their Receptors: From Past to Future
Current Medicinal Chemistry Acute Phase Treatment of Pulmonary Embolism
Current Vascular Pharmacology Healthy Properties of Garlic
Current Nutrition & Food Science Pharmacological and Non Pharmacological Strategies in the Management of Coronary Artery Disease and Chronic Kidney Disease
Current Cardiology Reviews Obesity and Cardiovascular Physiology: Impact of some Pharmacological Agents
Current Vascular Pharmacology The Trigeminocardiac Reflex as Oxygen Conserving Reflex in Humans: Its Ischemic Tolerance Potential
Vascular Disease Prevention (Discontinued) PPAR Ligands Containing Stilbene Scaffold
Mini-Reviews in Medicinal Chemistry Heart Rate Variability Indexes in Dementia: A Systematic Review with a Quantitative Analysis
Current Alzheimer Research Hypertension in Chronic Kidney Disease: Novel Insights
Current Hypertension Reviews Therapeutic Angiogenesis in Ischemic Heart Disease: Gene or Recombinant Vascular Growth Factor Protein Therapy?
Current Gene Therapy Editorial [Hot topic: Controversies in Hypertension Treatment (Guest Editors: Maciej Banach, Sverre E. Kjeldsen and Krzysztof Narkiewicz)]
Current Vascular Pharmacology The Fabry Cardiomyopathy - Diagnostic Approach and Current Treatment
Current Pharmaceutical Design The Kidney and the Sympathetic System: A Short Review
Current Clinical Pharmacology Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective
Current Neuropharmacology Mood Disorders in Elderly Population: Neurostimulative Treatment Possibilities
Recent Patents on CNS Drug Discovery (Discontinued)